Jara Atienza is a partner of the Corporate/Commercial Law Department at Garrigues Madrid.
Her professional practice covers a broad spectrum of corporate/commercial law matters, mergers and acquisitions, private equity transactions, venture capital, corporate restructurings, fund raising and on-going corporate and contractual advice to both national and international operators.
She is also a specialist in the life science sector, having participated in numerous M&A transactions in the sector and being a recurring advisor to many of the companies in the Spanish pharmaceutical, health and biotechnology sector.
She is a member of the Expert Committee of the Spanish Franchisers Association.
Jara Atienza joined the firm in September 2008 and was promoted to partner in November 2022.
Jara's practice focuses on mergers and acquisitions, private equity transactions, venture capital and fundraising.
Jara also regularly advises national and international groups on corporate restructuring, corporate and contractual matters.
She has worked for a wide range of sectors including food and beverage, cosmetics, technology, health tech, pharmaceutical, industrial, financial services, medical services, retail distribution and advertising.
Her specialities also include advising on franchise agreements and she is a member of the Expert Committee of the Spanish Franchisors Association.
- Degree in Law and Business Administration, Universidad Pontifica Comillas (ICADE, E-3).
- Executive Master’s Degree in Business Law, Centro de Estudios Garrigues in collaboration with Harvard Law School.
For years she has been a regular contributor to IFAES courses on Shares Sale and Purchase Agreements and Shareholders' Agreements . She also teaches on several programmes at Centro de Estudios Garrigues, including the International Honours Programme.
Jara Atienza is a member of the Madrid Bar Association.
She has co-authored the following articles:
- "Consideration of health apps as medical devices" (*) (Cuadernos de Derecho Farmacéutico)
- "Reference pricing: Formation of groups with presentations not placed on the market"(*) (Cuadernos de Derecho Farmacéutico)
(*) Originally published in Spanish. See Spanish CV for more details.